The success of tumor immunotherapy, while partial, confirms the existence and importance
of tumor immunosurveillance. CD8+ T cell recognition of tumor-specific peptides bound to …

Immunogenic cell death (ICD) is clinically relevant because cytotoxicants that kill malignant
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …

Simple Summary The aim of this innovative review is to highlight the treatment strategies
beyond immune-checkpoint inhibitor (ICI)-based first-line therapy failure according to …

Since the turn of the century, advances in targeted therapy and immunotherapy have
revolutionized the treatment of cancer. Although these approaches have far outperformed …

The age of personalized medicine continues to evolve within clinical oncology with the
arsenal available to clinicians in a variety of malignancies expanding at an exponential rate …

Background Patients with BRAF-mutant and wild-type melanoma have different response
rates to immune checkpoint blockade therapy. However, the reasons for this remain …

Background Combined inhibition of BRAF/MEK is an established therapy for melanoma. In
addition to its canonical mode of action, effects of BRAF/MEK inhibitors on antitumor immune …

Two pharmacologic approaches that are currently at the forefront of treating advanced
cancer are those that center on disrupting critical growth/survival signaling pathways within …

Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for
inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the …

Cancer research has seen unprecedented advances over the past several years, with
tremendous insights gained into mechanisms of response and resistance to cancer therapy …